Bioxytran (BIXT) Operating Expenses (2010 - 2026)
Bioxytran (BIXT) posted Operating Expenses of $1.9 million for Q1 2026, up 218.31% sequentially from $607285.0 in Q4 2025, and up 275.25% YoY from $515142.0 in Q1 2025.
Bioxytran (BIXT) Operating Expenses (2010 - 2026) Analysis & Trends
Bioxytran has reported Operating Expenses for 17 years, with the latest figure at $1.9 million in Q1 2026.
- Quarterly Operating Expenses rose 275.25% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 66.43% YoY) and the FY2025 annual result came in at $1.8 million, down 17.12% from the prior year.
- Operating Expenses improved to $1.9 million in Q1 2026 per BIXT's latest filing, from $607285.0 in the prior quarter.
- Over five years, Operating Expenses peaked at $1.9 million in Q1 2026 and troughed at -$14225.0 in Q3 2022.
- A 5-year average of $719728.6 and a median of $609322.0 in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses sank 102.6% in 2022, then jumped 7027.7% in 2023.
- Over 5 years, Operating Expenses stood at $1.1 million in 2022, then declined by 8.01% to $1.0 million in 2023, then tumbled by 51.5% to $488313.0 in 2024, then advanced by 24.36% to $607285.0 in 2025, then surged by 218.31% to $1.9 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $1.9 million, $607285.0, and $496005.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | 654,600.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.93 Mn |
| Dec 31, 2025 | 607,285.00 |
| Sep 30, 2025 | 496,005.00 |
| Jun 30, 2025 | 224,079.00 |
| Mar 31, 2025 | 515,142.00 |
| Dec 31, 2024 | 488,313.00 |
| Sep 30, 2024 | 346,204.00 |
| Jun 30, 2024 | 609,322.00 |
| Mar 31, 2024 | 779,229.00 |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 985,465.00 |
| Jun 30, 2023 | 1.06 Mn |
| Mar 31, 2023 | 750,242.00 |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | -14,225.00 |
| Jun 30, 2022 | 537,224.00 |
| Mar 31, 2022 | 819,106.00 |
| Dec 31, 2021 | 935,964.00 |
| Sep 30, 2021 | 547,243.00 |
| Jun 30, 2021 | 1.04 Mn |